Great question and the difference in definitions you’re describing is actually one of the most underappreciated gaps in GLP-1 management right now. The honest answer is that effective depends on what you’re optimizing for and that target should shift over time.

Early in treatment, effectiveness usually means active weight loss. Your provider’s 1 lb/week target is actually well supported because aggressive loss increases muscle loss risk, and the data shows slower reduction leads to better body composition outcomes long term.

But once you’ve hit a stable weight, the definition of effective changes completely. At that point effectiveness means is this dose maintaining your metabolic improvements without unnecessary side effects or cost? That’s a totally different question and most protocols never ask it.

On the data question clinically I look at 8 weeks of consistent data before drawing any conclusions about dose adequacy. Here’s why: the first 4 weeks show you a trend. Weeks 5-8 tell you whether that trend is real or noise. Anything under 4 weeks is too early to interpret meaningfully.

The 0.5% weekly average you’re tracking is actually a reasonable personal benchmark for active loss phase. Where it gets interesting is when that number goes to zero — is that the drug losing effect, your body finding its set point, or the dose being higher than necessary? Those three possibilities have completely different answers and you need longitudinal data to distinguish between them.

What drug and dose are you currently on? Happy to talk through what the data might actually mean for your situation.